BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » product launch

Axiogenesis Launches Cardio.Force, a Cardiac Contractile Force Assay Service

February 1, 2017 By Cade Hildreth (CEO) Leave a Comment

contractile force of the heart | Axiogenesis Launches Cardio.Force, a Cardiac Contractile Force Assay Service

contractility muscle | Axiogenesis Launches Cardio.Force, a Cardiac Contractile Force Assay ServiceAxiogenesis, a worldwide leading provider of induced pluripotent stem cell (iPS cell) products, has added a vital new service offering: Cardio.Force, a technology for measuring the contractile force of the heart. This newest service offering includes assay services for iPSC-derived cardiomyocyte functionality and toxicity assessment.

In this article:

  1. The Cardio.Force Technology
  2. Cardio.Force’s Efficiency
  3. The Existing “Gold Standard” for Cardiac Force Assessment
  4. Cor.4CE Technology Overview
  5. Additional Advantages of the Cardio.Force Assay Service

Contractile Force of the Heart | Cardio.Force Service

The Cardio.Force Technology

Cardio.Force is based on the Axiogenesis’s 8-channel Cor.4CE assay device. Currently, 96 well versions are in development for an increased cardiac output and the reduction of cost per data point.

decreased contractility of heart | Axiogenesis Launches Cardio.Force, a Cardiac Contractile Force Assay Service
(8 well measurement stage)

The utility of the technology was exemplified in a publication by Goßmann et al., “Mechano-Pharmacological Characterization of Cardiomyocytes Derived from Human Induced Pluripotent Stem Cells.” In the study, Goßmann concludes, “The measured data and simulations for pharmacologically unstimulated contraction resembled findings in native human heart tissue, while the pharmacological dose-response curves were highly accurate and consistent with reference data.”

Cardio.Force’s Efficiency

Such assay systems comprise the only cost-effective human in vitro technology that can measure the true cardiac contractile force of the heart. To date, common assay systems for quantitative measurement of contractility have been animal-based, which drive up cost and complexity. In contrast, the Cardio.Force assay offers an efficient system for pharmacological and toxicological studies using human cells that would otherwise require animal models or be more expensive/costly and with few cardiac outputs.

Cor.4U® human iPSC-derived cardiomyocytes are plated on extremely thin and highly flexible membranes for assessment of mechanobiological properties.

The Existing “Gold Standard” for Cardiac Force Assessment

Currently, the “Gold Standard” in toxicology and physiology has been isolated animal heart (Langendorff) preparations for contractility measurements. The Langendorff heart assay is a common in vitro approach used in pharmacological and physiological testing that allows cardiac contractile strength and heart rate to be determined without requiring an intact animal.[i]  The major disadvantages of this system are that it is still an animal model, is expensive, is costing $5-20K per compound, is technically challenging, and has relatively high variability.

Other emerging technologies using iPSC-derived cardiomyocytes require very high numbers of cells creating microtissues that make the technology very expensive, while the Cor.4CE system requires only 300K cells per sample measurement.

The Cor.4CE system is also reproducible and scalable, which gives it further cost advantages.

Secondary readouts that are being championed/currently pursued for analyzing and assessing cardiac contractility include impedance measurements, atomic force measurements, movement, and calcium flux analysis. These systems fail to consistently correlate with clinical data; in contrast, the Cor.4CE system does show the expected results including a positive frequency force relationship in reaction to beta-adrenergic stimulation (e.g., isoproterenol) can be observed, proving true force measurement.

Cor.4CE Technology Overview

The Axiogenesis’s Cor.4CE device involves the culture of validated human iPSC-derived cardiomyocytes (Cor.4U) on flexible membranes for a more physiological system. The Axiogenesis Cor.4CE Analysis software allows for derivation of the true contractile force of the heart from the measurement of the displacement of the membrane generated by the contracting cardiomyocytes. It allows for repeatable contractility measurements with unprecedented accuracy under physiological mechanical conditions. Optionally, Cor.4U cardiomyocytes can be co-cultured with Cor.4U fibroblasts in order to increase the physiological relevance of the cell system.

cardiac output normal | Axiogenesis Launches Cardio.Force, a Cardiac Contractile Force Assay Service
Example beat with assessed parameters

Additional Advantages of the Cardio.Force Assay Service

  • True force measurement in human iPSC-derived cardiomyocytes using proprietary Cor.4CE assay technology
  • Highly precise, standardized, and repeatable test system in defined/controlled culture conditions
  • Sensitive and predictive for cardiac safety pharmacology
  • Suitable for scale-up given low compound volumes, quick turnaround

In summary, the combination of Cor.4U with the Cor.4CE system is the first in vitro assay setup to measure the true contractile force of the heart of iPSC-derived cardiomyocytes in a system suitable for scale-up. The system provides an ideal tool to assess pharmacological, safety pharmacological, and toxicological effects of drug candidates on human cardiomyocytes.

 

If you found this article valuable, subscribe to BioInformant’s stem cell industry updates.

We are the industry leaders in stem cell research, with research cited by The Wall Street Journal, Xconomy, AABB, and Vogue Magazine. Bringing you breaking news on an ongoing basis, join more than half a million loyal readers, including physicians, scientists, investors, and philanthropists.

What is your opinion about the Cardio.Force technology of Axiogenesis? Share your thoughts in the comments section below.

Up Next: Cynata’s iPSC-derived Cell Therapeutic (CYP-001) Meets Safety & Efficacy Endpoints

 

Footnote

[i] Bell, R., Mocanu, M. & Yellon, D. Retrograde heart perfusion: The Langendorff technique of isolated heart perfusion. Journal of Molecular and Cellular Cardiology 50, 940-950 (2011).

 

Editor’s Note: This post was originally published on February 1, 2017, and has been updated for quality and relevancy.

Filed Under: iPS Cells, Stem Cell News Tagged With: Axiogenesis, cardiac, product launch

BioInformant Releases Mesenchymal Stem Cell Industry Report with Traditional Metrics and New Social Analytics

November 21, 2015 By Cade Hildreth (CEO) Leave a Comment

BioInformant Releases Mesenchymal Stem Cell Industry Report with Traditional Metrics and New Social Analytics

View on PRNewswire or read the full press release below.

PRESS RELEASE; Washington, DC; November 21, 2015 — BioInformant, the only market research firm to exclusively serve the stem cell sector, announces the release of its global strategic report, “Mesenchymal Stem Cells – Advances and Applications.” Published November 2015, it presents 250 pages of coverage for the rapidly-evolving mesenchymal stem cell (MSC) industry.

Called the “most innovative market research firm in the world,” BioInformant tracks MSC industry metrics using continuously maintained dashboards combined with systems to trigger alerts when data exhibits unexpected variation.

A unique attribute of BioInformant is that its management team comes from a BioInformatics background – the science of collecting and analyzing complex biological data. BioInformant is the only known research firm to apply these data analysis techniques to the field of market research. This is important, because 2015 saw the first “thaw and use” ink to make MSCs readily available for 3D printing (RoosterBio and CELLINK), a novel manufacturing approach to produce a nearly unlimited supply of MSCs from iPSCs derived from a single donor (Cynata Therapeutics), and the recommendation for approval of a MSC product in Japan (JR-031 developed by Mesoblast’s Japanese partner, JCR Pharmaceuticals Co. Ltd). It is clear that the scope of the MSC industry is expanding and advanced analytics are required.

The report describes the current status of MSC research, the ongoing clinical trials involving MSCs, late stage MSC clinical trials, and possible uses of MSCs in cell therapy. Because MSCs are a sub-segment of the broader cell therapy (CT) and regenerative medicine (RM) markets, it also gives an overview of the regenerative medicine industry and overall cell therapy industry.

Importantly, BioInformant is always innovating. It tracks traditional market metrics, which include trend rate data for MSC clinical trials, scientific publications, grants, patents, product launches, new market entrants, acquisitions, and industry deal-making. However, it also tracks recently discovered social analytics, which are metrics derived from social media sites, search engines, online advertising platforms, and more. It is the only known research firm to take this duel-approach to market analysis.

Founded in 2006 in Washington, DC, BioInformant is distinctively suited to tracking the MSC industry, because it has been following the industry for a decade, providing a robust database of historical data.

BioInformant research has been cited on prominent news outlets that include the Wall Street Journal, Nature Biotechnology, CBS News, Medical Ethics, the Center for BioNetworking, and more. BioInformant also serves notable clients across the stem cell spectrum, with Fortune 500 companies on its client list that include GE Healthcare, Pfizer, Goldman Sachs, Beckton Dickinson, and many more.

Click here to view the full Executive Summary and Table of Contents: https://bioinformant.wpengine.com/product/mesenchymal-stem-cells-advances-and-applications/.

About BioInformant

In addition to offering cutting-edge market intelligence, BioInformant operates a stem cell industry blog at www.BioInformant.com which is nearing 100K views per month and has a subscriber base of stem cell industry executives and investors approaching 10K. It is a company goal to reach 500K views by mid-2017.  BioInformant’s President/CEO, Cade Hildreth, is a media expert on stem cell industry topics, recently conducting interviews with the Wall Street Journal and Los Angeles Business Journal.

Press Contact

Cade Hildreth, President/CEO
Hildreth@BioInformant.com
703-859-7617

Filed Under: Cord Blood, MSCs, Stem Cells Tagged With: cellink, cynata, market report, mesenchymal stem cells, metrics, press release, product launch, RoosterBio, social analytics

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.